Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Recognizing the need for more devices to assist in the diagnosis and treatment of lung disease in patients with the novel coronavirus, the US Food and Drug Administration has relaxed its enforcement policy for X-ray, ultrasound and magnetic resonance imaging systems, as well as software for analyzing images.
“Increasing the availability of mobile and portable systems may increase options to image patients inside and outside of health care facilities, which could help to reduce the spread of COVID-19,” the agency says in an immediately-in-effect guidance document.
“Additionally, modified use of ultrasound imaging systems may expand the number of health care practitioners capable of performing this imaging technique,” the FDA adds.
The 23 April guidance, “Enforcement Policy for Imaging Systems Used During the Coronavirus Disease (COVID-19) Public Health Emergency,” will be revoked when the national public health emergency is over.
The guidance says some imaging systems “have the potential to be modified into mobile or portable systems” so COVID-19 patients can stay away from large health care facilities to avoid passing on the disease. The document provides a detailed listing of the types of imaging devices and software covered by the guidance.
The FDA goes on to say that “some of these products that are software-based have the potential to provide radiological findings that could aid a health care professional in diagnosis of a particular condition or monitoring of disease state/severity.”
Therefore, the agency says it will look the other way if manufacturers of imaging systems and software make modifications to their already FDA-cleared or -approved products, as long as the changes don’t create an undue risk. The guidance offers roughly three pages of examples of modifications that would and would not create such risk.
The FDA stresses in its guidance that any changes made to the hardware, software, materials or duration of use of imaging systems should be validated by firms. The agency lists an array of international standards manufacturers can use to do this, including those from the International Electrotechnical Commission (IEC), the Association for the Advancement of Medical Instrumentation (AAMI), the American National Standards Institute (ANSI) and the National Electrical Manufacturers Association (NEMA).
Companies that modify their products must document the changes in device master records and change control records, the guidance says. It further notes that labeling should be included to help users “better understand the product modifications,” and offers 11 suggestions for items that could be included in labeling.
The guidance further says the FDA won’t object to:
The guidance also notes the agency won’t “determine whether there is an accession number during the importation of shipments of diagnostic X-ray systems.”
Medtech Insight: global medical technology news & analysis
By Elizabeth Orr 18 Sep 2020
The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its...
Medtech Insight: global medical technology news & analysis
18 Sep 2020
The US FDA has been skeptical about remote testing, but independent consultant (and former Abbott human factors director) Ed Israelski...
In Vivo: strategic insights for life sciences decision-maker...
Explore how digital technologies are being used to address the disruption of clinical trials for drugs and medical technology caused by COVID-19. Stay current with insights from industry leaders, information on guidance and regulation, and an examination of how the challenges of this global crisis and the industry’s response to it may soon usher in a new era in worldwide healthcare.
Topics Coronavirus
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
In the continually evolving medtech competitive landscape, it is vital to stay up-to-date with key events. With Meddevicetracker, you’ll be able to anticipate upcoming filings, research clinical trial dates and data, and access market size information and expert forecasts, all in one place.
Get a window into what the leading players across the biopharma, medtech, and diagnostics industries are thinking, as well as important insight into what your competitors are doing. Build your strategy with In Vivo.
Looking for more products Product Finder
